Skip to content

Research on the Construction of Risk Warning Technology for Blindness Caused by Ischemic Fundus Disease in High-altitude Permanent Residents Based on Fundus Examination

Research on the Construction of Risk Warning Technology for Blindness Caused by Ischemic Fundus Disease in High-altitude Permanent Residents Based on Fundus Examination

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113433
Enrollment
Unknown
Registered
2025-11-28
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-altitude retinopathy and hypertensive retinopathy

Interventions

Control group:None
Observation group:None

Sponsors

The First Affiliated Hospital of the Army Medical University of the People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 27 Years

Inclusion criteria

Inclusion criteria: 1.Age between 20 and 27 inclusive; 2.The observation group needs to reside continuously in the high-altitude area for at least 1.5 years; The control group needs to live at an altitude of 300 meters or less for a long time and have no history of long-term high-altitude residence; 3.The lowest altitude of the residential area of the observation group is>4000m; 4.The best corrected visual acuity is >= 4.8; 5.Complete fundus examination data;

Exclusion criteria

Exclusion criteria: 1.Merge with other irreversible visual impairments such as glaucoma, age-related macular degeneration, optic nerve atrophy (non ischemic), corneal leukoplakia, eyeball atrophy, etc; 2.Complicated with systemic diseases (such as hypertension, diabetes, cardiac insufficiency, active malignant tumor, severe liver and kidney failure, etc.

Design outcomes

Primary

MeasureTime frame
Retinal examination results;

Secondary

MeasureTime frame
Hematological indicators;

Countries

China

Contacts

Public ContactHuang Xiaoyong

The First Affiliated Hospital of the Army Medical University of the People's Liberation Army of China

1176120922@qq.com+86 13508316090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026